Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

17 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-15

Study Completion Date

2020-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The 2020 pandemic of the coronavirus (SARS-CoV2) has lead to an increase in ARDS cases requiring invasive mechanical ventilation in the ICU (Intensive Care Unit).

The investigators hypothesize that airway pressure release ventilation (APRV) could be beneficial in patients with ARDS secondary to SARS-COV2 viral pneumonia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transpulmonary Driving Pressure in ARDS COVID19 Patients

NCT04381286

Mechanical Ventilation SARS-CoV-2 COVID-19

UNKNOWN

A Multicenter, Random Control Study :Early Use of Airway Pressure Release Ventilation (APRVplus) Protocol in ARDS

NCT03549910

Acute Respiratory Distress Syndrome

RECRUITING NA

Safety of Low PEEP Maneuvers During ARDS Management

NCT05922969

Acute Respiratory Distress Syndrome Positive End Expiratory Pressure

RECRUITING

Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry-Based Observational Study

NCT07284888

Acute Respiratory Distress Syndrome

RECRUITING

Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation

NCT01339533

Respiratory Failure Acute Lung Injury (ALI) Acute Respiratory Distress Syndrome (ARDS)

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lung protective mechanical ventilation is the cornerstone of ARDS management, reducing the work of respiratory muscles and optimizing gas exchange. However, it can be the source of deleterious effects, grouped under the terms of ventilator induced lung injury (VILI) and ventilator induced diaphragm dysfunction.

The protective ventilatory strategy has led to a significant improvement in the prognosis of ARDS patients, by reducing the volume of the air and oxygen mixture (lower tidal volume) delivered to the lungs and thus reducing the pulmonary stress and strain. However, this protective ventilation usually requires deep sedation and neuromuscular blockade to avoid deleterious patient-ventilator asynchrony.

Airway Pressure Release Ventilation (APRV) has been proposed to reduce patient-ventilator asynchrony and reduce the VILI. The operating principles of APRV are based on the presence of two pressure levels that are kept constant. Spontaneous breathing is possible at any time at both pressure levels if the patient is not deeply sedated or under neuromuscular blockade.

The investigators hypothesize that APRV mode could be beneficial on oxygenation and respiratory work in patients with ARDS secondary to SARS-COV2 viral pneumonia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ARDS COVID19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Airway Pressure Release Ventilation

Patients with COVID-19 ARDS requiring invasive mechanical ventilation in ICU, on Volume Assist Control ventilation (VAC) or Pressure Assist Control (PAC), are switched to airway pressure ventilation (APRV). If APRV doesn't lead to improvement in oxygenation the ventilatory mode is switched back to VAC or PAC ventilatory mode.

Airway pressure release ventilation

Intervention Type OTHER

Ventilator management strategy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Airway pressure release ventilation

Ventilator management strategy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients treated in Nancy University Hospital between 01/04/2020 and 31/06/2020 for COVID-19 ARDS, requiring invasive ventilation
* Trial of airway pressure release ventilation during the ICU stay

Exclusion Criteria

* Patients requiring veno-venous ECMO
* Patients unable to complete the 6-hour APRV trial due to poor tolerance : SpO2 decrease \< 90% on FiO2 70%, haemodynamic instability (MAP \< 65mmhg without vasopressors, or 0.5 mg/h increase in norepinephrine, ventilator asynchrony (respiratory rate \>35), hypercapnia (pH \< 7,25 or PaCO2 \>60mmHg)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No